Growth hormone shows promise in shrinking HIV's hiding spots
NCT ID NCT03091374
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether giving recombinant human growth hormone for 48 weeks could reduce the hidden HIV reservoir in people already on successful antiretroviral therapy (ART). The goal was to move toward a 'functional cure' where the body can control the virus without lifelong medication. Twenty-two HIV-positive adults with undetectable viral loads took part. The main focus was on safety and measuring changes in the size of the viral reservoir.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUMAN IMMUNODEFICIENCY VIRUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mcgill University Health Center
Montreal, Quebec, H4A 3J1, Canada